Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker
dc.contributor.author | Hormaechea-Agulla, D | en_US |
dc.contributor.author | Gomez-Gomez, E | en_US |
dc.contributor.author | Ibanez-Costa, A | en_US |
dc.contributor.author | Carrasco-Valiente, J | en_US |
dc.contributor.author | Rivero-Cortes, E | en_US |
dc.contributor.author | L-Lopez, F | en_US |
dc.contributor.author | Pedraza-Arevalo, S | en_US |
dc.contributor.author | Valero-Rosa, J | en_US |
dc.contributor.author | Sanchez-Sanchez, R | en_US |
dc.contributor.author | Ortega-Salas, R | en_US |
dc.contributor.author | Moreno, MM | en_US |
dc.contributor.author | Gahete, MD | en_US |
dc.contributor.author | Lopez-Miranda, J | en_US |
dc.contributor.author | Requena, MJ | en_US |
dc.contributor.author | Castano, JP | en_US |
dc.contributor.author | Luque, RM | en_US |
dc.date.accessioned | 2016-10-25T09:50:16Z | |
dc.date.available | 2016-09-02 | en_US |
dc.date.issued | 2016-12-01 | en_US |
dc.date.submitted | 2016-10-17T14:51:15.738Z | |
dc.identifier.issn | 0304-3835 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/16044 | |
dc.description | Funded by Instituto de Salud Carlos III and Fondos FEDER (PI13-00651, PI14/00005; co-funded by European Regional Development Fund/European Social Fund “investing in your futute”) MINECO (BFU2013-43282-R), Junta de Andalucía (BIO-0139, CTS-1406, PI-0639-2012, PI-0541-2013), and CIBERobn. CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain. | en_US |
dc.format.extent | 125 - 134 | en_US |
dc.relation.ispartof | CANCER LETTERS | en_US |
dc.subject | GOAT-enzyme | en_US |
dc.subject | Ghrelin | en_US |
dc.subject | Prostate cancer | en_US |
dc.subject | Biomarker | en_US |
dc.subject | Diagnosis | en_US |
dc.subject | Diabetes | en_US |
dc.title | Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1016/j.canlet.2016.09.022 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387522600013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 1 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 383 | en_US |
Files in this item
This item appears in the following Collection(s)
-
Centre for Endocrinology [560]